Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00150397 · ClinicalTrials.gov registry record · Phase 2
A Study of the Safety and Efficacy of Tofimilast in Adult Asthmatics
A Phase 2 study of Asthma, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 112
- Enrollment target
- 20
- Study locations
NCT00150397: Completed Phase 2 study of Asthma, sponsored by Pfizer.
NCT00150397 is a Phase 2 study of Asthma that has completed, run by Pfizer. The registered enrollment target is 112 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00150397, a Phase 2 study of Asthma, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 112 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an initial proof of concept, phase to study to assess the safety and efficacy tofimilast for the chronic maintenance treatment of adults with persistent asthma
Conditions Studied
Interventions
- DRUG Tofimilast
Study Locations (20)
California
- Pfizer Investigational Site - Encinitas
- Pfizer Investigational Site - Riverside
Massachusetts
- Pfizer Investigational Site - North Dartmouth
- Pfizer Investigational Site - Springfield
Tennessee
- Pfizer Investigational Site - Kingsport
- Pfizer Investigational Site - Nashville
Provincia de San José
- Pfizer Investigational Site - Barrio Aranjuez
- Pfizer Investigational Site - San José
Florida
- Pfizer Investigational Site - DeLand
Georgia
- Pfizer Investigational Site - Atlanta
Illinois
- Pfizer Investigational Site - Normal
Kentucky
- Pfizer Investigational Site - Madisonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2005-03 |
| Est. Completion | 2005-11 |
| Phase | Phase 2 |
What the finished NCT00150397 record still lists
NCT00150397 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 1 intervention - of which Tofimilast is the first listed.
NCT00150397 names 20 study sites across 16 states, led by California, Massachusetts, Tennessee.
Frequently Asked Questions
What is clinical trial NCT00150397 about?
NCT00150397 is a clinical study titled "A Study of the Safety and Efficacy of Tofimilast in Adult Asthmatics". This is an initial proof of concept, phase to study to assess the safety and efficacy tofimilast for the chronic maintenance treatment of adults with persistent asthma
What is the current status of trial NCT00150397?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 112 participants. The study started on 2005-03. Estimated completion is 2005-11.
What conditions does trial NCT00150397 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT00150397?
The interventions under investigation include: Tofimilast (DRUG).
Who is sponsoring clinical trial NCT00150397?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00150397 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00150397's enrollment target sits among peer trials
112 207th of 374 higher than 167 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia